Swiss National Bank Cuts Position in Hologic, Inc. (NASDAQ:HOLX)

Swiss National Bank lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 5.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 656,240 shares of the medical equipment provider’s stock after selling 36,500 shares during the quarter. Swiss National Bank’s holdings in Hologic were worth $47,308,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. General Partner Inc. purchased a new stake in shares of Hologic during the fourth quarter valued at approximately $26,000. Groupama Asset Managment grew its holdings in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its position in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares during the period. First Horizon Advisors Inc. lifted its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on HOLX. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research report on Monday, February 3rd. Citigroup decreased their price target on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Finally, Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Performance

HOLX opened at $60.71 on Monday. The stock has a market capitalization of $13.62 billion, a price-to-earnings ratio of 19.15, a PEG ratio of 2.14 and a beta of 0.97. The company has a fifty day moving average of $67.18 and a 200 day moving average of $74.64. Hologic, Inc. has a fifty-two week low of $60.33 and a fifty-two week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.